Tumour-infiltrating lymphocytes (TILs) in breast cancer: A predictive or a prognostic marker?

Current Breast Cancer Reports

Volumn 7, Issue 1, 2015, Pages 59-70

  Dushyanthen, Sathana ^a   Savas, Peter ^a   Willard Gallo, Karen ^b   Denkert, Carsten ^c,d   Salgado, Roberto ^e   Loi, Sherene ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b JULES BORDET INSTITUTE   (Belgium)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Breast cancer; Immunity generation; Immunity suppression; TILs; Tumour infiltrating lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; DOCETAXEL; TRASTUZUMAB;

BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL INFILTRATION; CYTOTOXICITY; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PREDICTION; REVIEW; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84938424356     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-014-0178-4     Document Type: Review

References (99)

1. + lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14(2):R48.
2. Ono M et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132(3):793–805.
3. West NR et al. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2013;108(1):155–62.
4. Yamaguchi R et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012;43(10):1688–94.
5. Sun S et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014;63(4):395–406.
6. Loi, S., et al., Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Res, 2013. 73: p. abstract S1-05.
7. Adams S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–66.
8. Loi S et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial. Ann Oncol. 2014;25(8):1544–50. This study shows the benefit of TILs in different breast cancer subtypes. It shows an association between higher levels of TILs and decreased distant recurrence rates in primary TNBC as well as increased trastuzumab benefit in HER2+ disease.
9. Ali HR et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25(8):1536–43.
10. Denkert C et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–13.
11. Issa-Nummer Y et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer—a substudy of the neoadjuvant GeparQuinto trial. PLoS One. 2013;8(12):e79775.
12. Denkert, C., et al., Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66), in SABCS2013: San Antonio, Texas, USA.
13. Cortazar P et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.
14. Loi S et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7.
15. Perez, E.A., et al., Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. J Clin Oncol, 2014. 32: p. abstr 509.
16. Baselga J et al. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol. 2014;32(33):3753–61.
17. Lee S et al. Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol. 2013;52(1):73–81.
18. Seo AN et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705–13.
19. Demir L et al. Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3+ Tregs. Clin Exp Metastasis. 2013;30(8):1047–62.
20. Melichar B et al. Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. Anticancer Res. 2014;34(3):1115–25.
21. Koh YW et al. Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting. Tumour Biol. 2014;35(10):9823–30.
22. Mahmoud S et al. CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker? Oncoimmunology. 2012;1(3):364–5.
23. Mohammed ZM et al. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2013;109(6):1676–84.
24. Schatton T et al. Tumor-infiltrating lymphocytes and their significance in melanoma prognosis. Methods Mol Biol. 2014;1102:287–324.
25. Garcia-Martinez E et al. Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res. 2014;16(6):488.
26. Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12(12):1597–611.
27. Gu-Trantien C et al. CD4(+) follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873–92.
28. Godet Y et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res. 2012;18(10):2943–53.
29. Chen Z et al. Intratumoral CD8(+) cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One. 2014;9(4):e95475.
30. Rathore AS et al. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast. Indian J Med Res. 2014;140(3):361–9.
31. Song G et al. Elevated level of peripheral CD8(+)CD28(−) T lymphocytes are an independent predictor of progression-free survival in patients with metastatic breast cancer during the course of chemotherapy. Cancer Immunol Immunother. 2013;62(6):1123–30.
32. Bos R et al. Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology. 2012;1(8):1239–47.
33. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70(21):8368–77.
34. de Leeuw RJ et al. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: A critical review of the literature. Clin Cancer Res. 2012;18(11):3022–9.
35. Takenaka M et al. FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol. 2013;1(4):625–32.
36. Droeser R et al. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer. 2012;12:134.
37. Faghih Z et al. Immune profiles of CD4+ lymphocyte subsets in breast cancer tumor draining lymph nodes. Immunol Lett. 2014;158(1–2):57–65.
38. Ruffell B et al. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012;109(8):2796–801.
39. Gooden MJ et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103.
40. Krell J, Frampton AE, Stebbing J. The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter? BMC Cancer. 2012;12:135.
41. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunology. 2013;2(7):e24720.
42. Cimino-Mathews A et al. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: A pilot study. Hum Pathol. 2013;44(10):2055–63.
43. Kim ST et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol. 2013;36(3):224–31.
44. Jia Y et al. Levels of lymphocyte subsets in peripheral blood prior treatment are associated with aggressive breast cancer phenotypes or subtypes. Med Oncol. 2014;31(6):981.
45. Hix LM et al. Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells. J Biol Chem. 2013;288(17):11676–88.
46. Boyle ST, Kochetkova M. Breast cancer stem cells and the immune system: promotion, evasion and therapy. J Mammary Gland Biol Neoplasia. 2014;19(2):203–11.
47. Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. 2014;15(2):e58–68.
48. Dong DD et al. Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. Hum Immunol. 2012;73(10):998–1004.
49. Roscilli G et al. Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients. J Transl Med. 2014;12:54.
50. Chawla A et al. Immune aspects of the breast tumor microenvironment. Breast Cancer Manag. 2013;2(3):231–44.
51. Schirrmacher V et al. T cell memory, anergy and immunotherapy in breast cancer. J Mammary Gland Biol Neoplasia. 2002;7(2):201–8.
52. Schalper KA. PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer. Oncoimmunology. 2014;3:e29288.
53. Mamessier E et al. “Stealth” tumors: breast cancer cells shun NK-cells anti-tumor immunity. Oncoimmunology. 2012;1(3):366–8.
54. Mamessier E et al. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 2011;71(21):6621–32.
55. Mamessier E et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011;121(9):3609–22.
56. da Cunha A, Michelin MA, Murta EF. Pattern response of dendritic cells in the tumor microenvironment and breast cancer. World J Clin Oncol. 2014;5(3):495–502.
57. Liu Q et al. Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation. J Biol Chem. 2014;289(16):11522–35.
58. Kadam CY, Abhang SA. Serum levels of soluble Fas ligand, granzyme B and cytochrome c during adjuvant chemotherapy of breast cancer. Clin Chim Acta. 2015;438:98–102.
59. Bebenek M, Dus D, Kozlak J. Prognostic value of the Fas/Fas ligand system in breast cancer. Contemp Oncol (Pozn). 2013;17(2):120–2.
60. Holt DM et al. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother. 2012;35(2):179–88.
61. Bergenfelz C et al. Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. J Immunol. 2012;188(11):5448–58.
62. Gelao L et al. Dendritic cell-based vaccines: clinical applications in breast cancer. Immunotherapy. 2014;6(3):349–60.
63. Campbell MJ et al. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013;8(10):e79114.
64. Deng R et al. Dimethyl sulfoxide suppresses mouse 4T1 breast cancer growth by modulating tumor-associated macrophage differentiation. J Breast Cancer. 2014;17(1):25–32.
65. Nickerson NK et al. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. Oncol Res. 2013;20(7):303–17.
66. Schalper KA et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773–82.
67. Kmieciak M et al. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol. 2011;187(2):708–17.
68. Wang Z et al. Quantitative assessment of the association between three polymorphisms in FAS and FASL gene and breast cancer risk. Tumour Biol. 2014;35(4):3035–9.
69. Verma C et al. Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med. 2013;11:16.
70. Liu S et al. Prognostic significance of FOXP3+ tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014;16(5):432. This study showed that FOXP3+ regulatory TILs are a poor prognostic indicator in ER-positive breast cancer, but a favorable prognostic factor in the HER2+/ER-negative subtype, thus revealing that the prognostic value of FOXP3+ TILs differs depending on ER and HER2 expression status and CD8+ T cell infiltration.
71. Lal A et al. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast. Breast Cancer Res Treat. 2013;139(2):381–90.
72. Forghani P, Khorramizadeh MR, Waller EK. Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer. Cancer Med. 2014;3(2):215–24.
73. Alizadeh D et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014;74(1):104–18.
74. Yu J et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013;190(7):3783–97.
75. Singh R et al. Proteomic identification of mitochondrial targets of arginase in human breast cancer. PLoS One. 2013;8(11):e79242.
76. Markowitz J et al. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013;140(1):13–21.
77. Liu H et al. Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK92 cells. Oncol Rep. 2015;33(1):95–102.
78. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
79. Alistar A et al. Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med. 2014;6(10):80.
80. Jiang X. Harnessing the immune system for the treatment of breast cancer. J Zhejiang Univ Sci B. 2014;15(1):1–15.
81. Wolchok JD, Chan TA. Cancer: Antitumour immunity gets a boost. Nature. 2014;515(7528):496–8.
82. Mao H et al. New insights of CTLA-4 into its biological function in breast cancer. Curr Cancer Drug Targets. 2010;10(7):728–36.
83. Jaberipour M et al. Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathol Oncol Res. 2010;16(4):547–51.
84. Muenst S et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2014;146(1):15–24.
85. Muenst S et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139(3):667–76.
86. Gubin MM et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577–81.
87. Herbst RS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7. This paper reveals that responses to anti-PD-L1 were observed in patients expressing high levels of PD-L1, particularly in TILs. They showed that it was most effective in patients with pre-existing immunity suppressed by PD-L1 and that immunity was reinvigorated on antibody treatment.
88. Powles T et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–62.
89. Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.
90. Deng L et al. Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression. Oncoimmunology. 2014;3:e28499.
91. Deng L et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–95.
92. Li F et al. Anti-tumor immunological response induced by cryoablation and anti-CTLA-4 antibody in an in vivo RM-1 cell prostate cancer murine model. Neoplasma. 2014;61(6):659–71.
93. Yoshimoto Y et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One. 2014;9(3):e92572.
94. Kvistborg P et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6(254):254–128. This paper showed that anti-CTLA-4 treatment induces T cell responses and infrequently boosts pre-existing immune responses, providing evidence of anti-CTLA-4 therapy-induced T cell priming as a component of the clinical mode of action.
95. Klyushnenkova EN et al. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. Prostate. 2014;74(14):1423–32.
96. Fourcade J et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res. 2014;74(4):1045–55.
97. da Silva IP et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014;2(5):410–22.
98. Salgado, R., et al., The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann Oncol, 2014. This paper highlights the importance of TIL measurement in breast cancer and provides a detailed standardized methodology for evaluating TILs in histopathological practice, in a research setting as well as in clinical trials.
99. Salgado R, et al. Harmonization of the evaluation of tumour-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs-working group 2014 Ann Oncol mdu450 first published online September 11, 2014 doi: 10.1093/annonc/mdu450. By permission of Oxford University Press on behalf of the European Society for Medical Oncology